Form 10-K Arcturus Therapeutics For: Dec 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Arcturus Therapeutics (ARCT) PT Lowered to $65 at Leerink Partners
March 7, 2025 5:47 AM ESTLeerink Partners analyst Lili Nsongo lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $65.00 (from $70.00) while maintaining a Outperform rating.
The analyst comments "Bottom Line: Today after close, ARCT reported FY24 earnings and provided a pipeline update. In the partnered vaccine... More
